BBS2

BBS2 is one of a family of genes named for Bardet-Biedl syndrome, and the protein it makes joins seven other BBS proteins to form the BBSome. The BBSome works at the cilium, and many BBS proteins gather at the base of cilia and help move cargo along microtubule tracks inside cells. Photoreceptors, the light-sensing cells of the retina, depend on a specialized cilium to function. When these don't function properly, vision is adversely affected. BBS2-related disease is inherited in an autosomal recessive (definition: An inheritance pattern where a person needs an altered copy of a gene from both parents to be affected. Parents with only one copy are usually unaffected carriers.) way, meaning a person typically has a disease-causing change in both copies of the gene, one from each parent. The gene also carries the alternative name RP74, reflecting its recognized role in retinitis pigmentosa.

Retinal degeneration is a consistent feature of BBS2-related disease. Many people experience night blindness and a gradual loss of side (peripheral) vision, a pattern doctors call rod-cone dystrophy or retinitis pigmentosa. The degeneration can be early and severe; in one long-standing report of families used to first identify BBS2, the retinal disease led to legal blindness in the second decade of life. In a Saudi cohort of Bardet-Biedl syndrome, most patients had advanced retinal disease and were legally blind by early adulthood, and the predominant pattern there was cone-rod dystrophy rather than the classic rod-first pattern. The severity is not the same for everyone, and in a Chinese cohort people with two missense changes in BBS2 tended to have milder symptoms and less visual impairment. Importantly, some people with BBS2 changes have retinal disease without the other body-wide features, an apparently non-syndromic retinitis pigmentosa.

BBS2 is an established cause of retinal disease, appearing both in Bardet-Biedl syndrome and in retinitis pigmentosa limited to the eyes. Across several regional studies, BBS2 is among the more frequently involved BBS genes, being one of the two most common in Chinese and Indian cohorts. A specific BBS2 change, c.471G>A, has been reported as a founder variant in Baloch families and other patients from Iran, meaning it recurs in that population from a shared ancestor. When BBS2 disease is syndromic, reported features beyond the eyes include obesity, extra fingers or toes (polydactyly), kidney and genitourinary abnormalities, and learning difficulties. A meta-analysis of BBS patients found that core BBSome subunits such as BBS2 appear more critical for kidney development and function than some other BBS proteins.

It is not possible to predict from a BBS2 result alone whether a given person will have a full syndrome or eye-only disease. Wide variability has been seen even among relatives carrying the same BBS2 change, and researchers have not established a clear correlation between the specific variant and the eye outcome. Because some Bardet-Biedl features appear only with age, a person diagnosed with non-syndromic disease may later be found to have subtle extra-ocular features on careful re-examination. One report proposed that rare changes in BBS2 combined with a change in another gene, AIPL1, might together contribute to retinal disease, but this idea rests only on computer modeling and has not been confirmed in the laboratory.

No therapy has been approved that targets the BBS2 gene or reverses the retinal degeneration it causes. On the research side, a laboratory study modeled BBS2 changes in cultured cells and in zebrafish, where loss of the gene led to cone degeneration and misplaced photoreceptor (definition: A light-sensing cell in the retina. Rods (used for night and peripheral vision) and cones (used for color and detail) are the two types.) proteins — findings that help explain the disease but are not treatments. Separately, in a mouse model of the related gene BBS10, researchers documented progressive retinal degeneration as groundwork for future gene therapy (definition: A treatment that delivers a working copy of a gene into cells to take over for a copy that isn't functioning properly.), again in animals rather than people and not specific to BBS2.

• BBS2 changes can cause retinitis pigmentosa without the full syndrome

  Human case report combined with laboratory and animal (zebrafish) research; this record is a preprint.

  What was found:

  The siblings had two BBS2 variants and features of retinitis pigmentosa but not the full Bardet-Biedl syndrome, and in zebrafish loss of the gene caused cone degeneration and misplaced rhodopsin.

  Why it matters:

  It supports the finding that BBS2 can cause eye-limited retinal disease and helps explain how the gene keeps photoreceptors healthy.

  Limitation: Only one family was described and the animal work does not directly predict outcomes in people.

• Wide variability in a Chinese cohort with BBS gene changes

  Observational human cohort study.

  What was found:

  BBS2 was one of the two most common genes, presentations ranged from full syndrome to non-syndromic retinitis pigmentosa, and people with two missense BBS2 changes tended to have milder disease.

  Why it matters:

  It shows how differently BBS2 disease can present and that milder eye disease is possible with certain variants.

  Limitation: Findings come from a single-region cohort and cannot be assumed to apply to every population or individual.

• Reverse phenotyping uncovers hidden syndromic features

  Observational human cohort study with genotype-guided re-evaluation.

  What was found:

  Careful re-examination revealed previously unrecognized features such as obesity, extra digits, and kidney anomalies, reclassifying many as having Bardet-Biedl syndrome.

  Why it matters:

  It shows why a BBS2 result may warrant looking beyond the eyes, since subtle body-wide features can be missed early.

  Limitation: The cohort was small and from one region, and diagnostic labels depended on which criteria were applied.

• Comparing BBS genes for organ involvement

  Meta-analysis of previously published human cases.

  What was found:

  Core BBSome subunits including BBS2 were linked to more kidney involvement than some other BBS proteins, suggesting the specific gene partly shapes the outcome.

  Why it matters:

  It highlights kidney monitoring as particularly relevant for people with BBS2 changes.

  Limitation: Combining data from many separate reports can introduce inconsistencies, and it does not predict any one person's course.

• Retinal features and outcomes in a Saudi BBS cohort

  Observational human cohort study.

  What was found:

  Most had advanced retinal disease and were legally blind by early adulthood, with cone-rod dystrophy the most common pattern and undetectable electroretinograms in nearly all.

  Why it matters:

  It illustrates how early and severe the retinal disease can be and notes a narrow window for any future rescue treatment.

  Limitation: It reflects one referral center and mixes several BBS genes, so it is not specific to BBS2.

BBS2 can involve more than the eyes, so families may need to watch for and monitor obesity, kidney and genitourinary problems, extra fingers or toes, and learning or developmental differences. Because kidney involvement is more likely with core BBSome genes such as BBS2, ongoing kidney monitoring can be an important part of care. Coordinated, multidisciplinary follow-up has been recommended for Bardet-Biedl syndrome, often involving several specialties over a person's life. Since the condition is autosomal recessive (definition: An inheritance pattern where a person needs an altered copy of a gene from both parents to be affected. Parents with only one copy are usually unaffected carriers.), siblings of an affected child may be carriers or affected, which is a useful point to raise with a genetic counselor.

• Do my genetic results and eye findings point toward non-syndromic retinal disease or toward Bardet-Biedl syndrome?
• Given the possibility of body-wide involvement, which other specialists or screenings (for example kidney, metabolic, or developmental) would you recommend?
• What pattern of retinal degeneration do my tests show, and what might that mean for how my vision changes over time?
• Would additional testing of family members or genetic counseling be useful for my relatives?
• Are there monitoring schedules you recommend for the non-eye features sometimes seen with BBS2?
• How can I use the Clinical Trials Finder to see whether any studies might apply to my situation?

Confirming the genetic diagnosis and reviewing what it means with a genetic counselor is a helpful first step. Because BBS2 can be associated with features outside the eye, a thorough evaluation for things such as weight, kidney function, and other body systems may be worth discussing with your care team, even if the diagnosis was originally eye-only. To explore whether any current studies may be relevant, you can use RP Hope's Clinical Trials Finder with BBS2 preselected rather than judging eligibility on your own. RP Hope's guided pathway and patient stories can help you find further resources and connect with others navigating similar diagnoses.